BB-Cl-Amidine hydrochloride
中文名称 | BB-Cl-Amidine hydrochloride |
---|---|
中文同义词 | 化合物 T10482L |
英文名称 | BB-Cl-Amidine hydrochloride |
英文同义词 | BB-Cl-Amidine hydrochloride |
CAS号 | |
分子式 | C??H??Cl?N?O |
分子量 | 0 |
EINECS号 | |
相关类别 | |
Mol文件 | Mol File |
结构式 |
BB-Cl-Amidine hydrochloride 性质
PAD.
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.
Animal Model: | MRL/lpr mice. |
Dosage: | 1 mg/kg. |
Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. |
Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |